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Abstract
New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have
successfully discovered treatments with moderate but worthwhile eﬀects to prevent heart attack and stroke. The design of
these trials may hold lessons for the dementia prevention.
Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We
consider what features are needed to maximise eﬃciency. Populations could be selected by age, clinical or genetic risk factors
or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels
of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential
patients and can be measured in large trials.
The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and
will need collaboration between many clinical investigators, funders and patient organisations.
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Key points:
• Large simple trials have transformed care for heart attack and stroke. Lessons from these trials may be applicable to dementia
prevention.
• The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge. The
reliable identiﬁcation of higher risk populations is diﬃcult but will be important.
• Patients and families prioritise loss of function. Loss of functional abilities or clinical dementia are infrequent, but might
be measured with lower variability than cognitive scores.
Dementia is a major healthcare and social challenge, but
there is no available treatment to delay its onset or pro-
gression. Despite poor progress to date, optimism remains
that new agents or novel strategies of evaluation will be
eﬀective.
Here we analyse the possible populations, interventions,
outcomes and designs relevant to randomised trials to test
new interventions targeting dementia incidence. We con-
centrate on eﬃcient and reliable designs that could reduce
costs for academic trialists, and examine whether the design
of large trials that have led to the successful preventative
strategies in cardiovascular disease are relevant to dementia
prevention.
Populations at high risk and populations
for long-term follow-up
An ideal trial population for dementia prevention would
be easily identiﬁed, highly motivated to participate, with a
high risk of dementia within a short follow-up. Populations
could be identiﬁed by age, clinical and polygenic scores for
dementia, high-risk polymorphisms, frailty or mild cognitive
impairment (MCI).
Although age is a strong risk factor for dementia, the
incidence of dementia even in the oldest old is modest (85
per 1000 person years at age 85 years and above). [1] Any
advantage of recruiting the very old might be mitigated by
their competing risk of death. The annual mortality rate of
80–84 year-olds: is 6%, so there would be substantial loss-
to-follow-up over a ﬁve-year trial. [2] However, healthy older
people can be identiﬁed simply, in large numbers, and are
highly motivated to prevent a dementia which many will
have experienced through family or friends. [3]
Dementia risk prediction scores based on clinical variables
could be implemented in electronic records to identify high-
risk populations, but the best score is not obvious. Some are
poorly validated [4,5] and it is unclear which score identiﬁes
the highest risk population. [6,7] Risk scores are acceptable
to participants. The Finnish Geriatric Intervention Study
to Prevent Cognitive Impairment and Disability (FINGER)
used a threshold of a risk score to identify suitable partici-
pants, although most of those surveyed for eligibility (84%)
already had a high score, so the beneﬁt of using the risk score
was small. [8,9]
Available polygenic scores only explain a modest propor-
tion of the variance in dementia incidence at younger ages,
[10] but might perform better at older ages. [11] Although
measurement of polygenic scores adds complexity, the cost
of a gene chip is modest. Potential participants who are
APOE ε4 carriers and have elected not to be informed of
the results of their genetic tests could be approached from
existing registers, but the gain in the number of dementia
cases in a recruited population who are APOE4 positive or
have higher polygenic scores is likely to be modest compared
with easier to approach populations such as those with a
family history of dementia, or a higher clinical risk score
(see Table 1).
Participants with some evidence of impairment on cogni-
tive tests but normal activities of daily living, i.e. with MCI,
are at higher risk of dementia compared with those with no
cognitive impairment.However, the clinical course ofMCI is
not always predictable: patients may improve, remain stable
or progress to dementia. [12] MCI prognosis depends very
much on the setting. In specialist clinics, ∼10% develop
dementia annually, compared with ∼5% in the community.
Incidence further depends on age, APOE and cognitive
status. [13,14] Because of diﬀerences in these characteristics,
trials recruiting participants with MCI have had varying
progression to dementia.
The approach to potential participants is important.
Although post is cheap, response rates are poor compared
with in-person approaches. For example, in a trial of com-
puterised cognitive training, only 5% of those approached by
post consented. [15] However in the FINGER study where
participants who had previously taken part in health surveys,
had a high response to a screening invitation (43–57%) of
whom approximately half took part. [9]
Choosing interventions to prevent
dementia onset
It is clear that amyloid plaques are important markers of
Alzheimer’s disease and that mutations in amyloid processing
lead to early onset dementia. This is supported by pathway
analyses of genome wide association studies (GWAS). [16]
However, drugs targeting soluble and insoluble amyloid,
amyloid pre-processing and vaccines against amyloid have
yet to be shown deﬁnitively to be eﬀective. This may be
because of adverse eﬀects, [17] low amyloid positivity in
trial participants or that intervention needs to be given at
the very earliest stages of amyloid accumulation. Moreover,
amyloid burden correlates only modestly with cognitive
2
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Table 1. Proportion of patients developing dementia at
10 years, estimated from the Rotterdam study [6]
Characteristics Age at recruitment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 70 75
% Dementia by 10 years
No memory complaints 4 5 8
No memory complaints + APOE ε4 positive 6 10 15
No memory complaints + history of stroke 6 10 15
No memory complaints, but diﬃculties with
IADL
5 8 12
Memory complaints, but no diﬃculties with
IADL
5 7 11
IADL: instrumental activities of daily living (ﬁnance or medication).
and behavioural deﬁcits, [18] and removal of brain amy-
loid [assessed by positron emission tomography (PET) or
cerebrospinal ﬂuid (CSF) studies] has yet to correlate with
clinically meaningful improvements in cognition. Targeting
tau protein has shown promise in animal models, and clinical
trials run by pharmaceutical companies are testing anti-tau
agents in phase 2 and phase 3 trials. [19]
Inﬂammatory pathways are appealing because several
agents target single or multiple inﬂammatory pathways.
Although GWAS supports inﬂammatory mechanisms as
a cause of dementia, [16] animal studies suggest that
inﬂammation (i.e. microglial activation) has both beneﬁcial
and harmful eﬀects in the brain that may vary over the course
of disease, and therefore the optimal intervention period is
uncertain. [20]
Lipids are of particular interest because the ε4 allele of
APOE is a strong risk factor for Alzheimer’s disease. People
with an ε4 allele have higher total cholesterol (∼0.25–
0.5mmol/L) and triglycerides than those without, and there-
fore higher blood cholesterol is one potential mechanism for
the eﬀect of the ε4 allele. [21] In the brain, the role of APOE
is less certain. GWAS studies also show the importance of
cerebral lipid metabolism as a risk factor for Alzheimer’s
disease. [16] However, new approaches to managing lipids
are needed as blood cholesterol lowering agents have so far
been neutral for dementia prevention. [22]
Currently, the most plausible, modiﬁable targets for
dementia prevention are other cardiovascular risk factors,
chieﬂy high blood pressure and diabetes. Biological mecha-
nisms link the cerebral vasculature with Alzheimer’s disease
and neurodegeneration. [20,23] Vascular damage leads to
blood brain barrier breakdown, parenchymal accumulation
of neurotoxic moieties, inﬂammation and synaptic dysfunc-
tion and accumulation of Aβ and tau through failure to
clear proteins along perivascular spaces and through aberrant
metabolism. [20]The earliest physiological change in human
carriers of APOE ε4 is vascular dysfunction, and in apoe ε4
animal models early degeneration of vascular endothelial
cells and pericytes. [20] Observational cohorts demonstrate
associations between higher dementia risk with higher mid-
life blood pressure, [24] poorer sleep, [25] less exercise [26]
and diabetes, [27] but the association between polygenic
scores of hypertension, LDL cholesterol and diabetes with
Alzheimer’s dementia has been inconsistent. [28]
It is uncertain why blood pressure lowering or statins—
which reduce the risk of stroke by about a ﬁfth—do not lead
to a consistently detectable reduction in dementia incidence.
This may be because dementia prevention needs a longer
duration of therapy or a greater intensity of intervention
as in Systolic Blood Pressure Intervention Trial (SPRINT-
MIND) [29] in comparison to the prevention of myocardial
infarction and stroke. [30]
Although most potential treatments for dementia have
a biological or epidemiological rationale, choosing a single
candidate with the highest chance of success is diﬃcult. One
approach is to start with systematic reviews of experiments
in model systems, genetic studies, or of early stage human
trials. For example, an adaptive trial in progressive multiple
sclerosis has used systematic reviews to identify candidate
agents [31]. The selection process began with systematic
review of the in vivo experimental data, which identiﬁed
candidate agents. These candidates were further winnowed
based on safety data, eﬃcacy, risk of bias of the underlying
literature, the number of patients contributing evidence,
biological plausibility and central nervous system penetra-
tion. [32] Further selection of agents can be made with
an adaptive trial design. Multi-arm adaptive trials use pre-
speciﬁed rules to select between agents during the course
of the trial (e.g. by measuring the eﬀects of diﬀerent agents
on a responsive biomarker), so unsuccessful agents can be
rejected, and successful ones taken forward to the later trial
stages. However, for such a trial to be successful for dementia
outcomes would need a responsive biomarker signal that
would be expected to change more quickly than clinical
variables (see below).
What cognitive outcomes should be
measured?
Variability during the serial measurement of cognition
potentially obscures treatment eﬀects. Contributing to
this variability are sleep quality, anxiety and variation in
circumstances of test administration e.g. diﬀerent examiners
and noisy or poorly-lit rooms. In addition, any single
cognitive test is not likely to be sensitive to all cognitive
domains. Therefore, small but clinically relevant treatment
eﬀects could go undetected.
Variability could be reduced by repeating cognitive
tests—analogous to other continuous variables such as
blood pressure—but this could come with increased cost,
more missing data and learning eﬀects. Large international
trials pose particular problems for trials aiming to measure
cognition and function that may diﬀer by world region
and culture. Better training, especially in the diﬀerences in
language and culture, might help, as well as the development
of scales that take into account the diﬀerences expected
between countries and groups of people. [33]
There is a tension between the complexity of cognitive
tests and the resources available to perform them in most
3
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settings. In highly resourced trials (such as the SPS3 [34])
extended cognitive batteries can be performed, increasing
costs and limiting populations to those easily followed up.
Although short tests do not cover all cognitive domains,
they are simple to perform at large scale and demonstrate
cognitive decline in patients who are in the later stages of
disease. [35]
An alternative to cognitive testing is to measure the
time taken to reach clinically meaningful milestones i.e.
the diagnosis of dementia or MCI. Clinical outcomes and
other functional thresholds have greater meaning to patients
and clinicians than cognitive scores. In SPRINT-MIND, the
use of an adjudicated clinical milestone (the development of
dementia or two consecutive adjudicated MCI events) was
critical to accrue enough events reliably to demonstrate an
eﬀect in an analysis of intensive BP lowering on dementia
or MCI. [29] These adjudicated outcomes were resource
intensive to measure and had greater face-validity.
The measurement of clinical outcomes implies the mea-
surement of both function and cognition. The measurement
of both means disease trajectories can continue to be mea-
sured later into the disease course, where the recruitment of
a friend or family member would allow the report of function
when cognition was diﬃcult to measure and hence could
reduce loss-to-follow-up.
Trial design
Large simple trials have been inﬂuential in other areas of
medicine. Vascular researchers pioneered large-scale ran-
domised trials [37] which led to widespread adoption of
treatments that have contributed to decreasing the burdens
of stroke, myocardial infarct, diabetes and other vascular
diseases in high income, and to some extent in low- and
middle- income countries. [38,39] The application of eﬃ-
cient, simple trial designs to target dementia mean trials can
be larger, allowing more precise estimates of treatment, and
greater generalisability of therapies at similar or lesser cost
than trials of high complexity.
Thus far, the bulk of the clinical trial designs in dementia
prevention has used labour-intensive examinations, applica-
tion of expensive technology and relatively short follow-up
based on cost and other design limitations. Large trials are
probably necessary in dementia prevention, because:
Effect sizes are likely to be moderate, because
multiple pathologies lead to cognitive impairment
in most individuals
Protein folding disorders, vascular pathologies and inﬂam-
mation are found together in many—up to two-thirds—
patients with dementia. [40,41] If agents are eﬃcacious
for one of these multiple pathologies and all pathologies
contribute to varying extent to the clinical phenotype
(although Alzheimer’s pathology is most commonly found),
we can expect only moderate eﬀects on overall dementia
incidence or cognitive decline. Large numbers must be
recruited to a trial with clinical outcomes to reliably assess
for moderate beneﬁts.
Loss of clinically meaningful function, and dementia,
are important outcomes but are less frequent than
small changes in cognitive scores over short periods
of time.
For disabling diseases, preventing or delaying loss of clini-
cally meaningful function provides a better test of eﬃcacy
than improving cognitive tests, imaging or other biomarkers.
Outcomes that cross important functional boundaries are
the most important to older people. [42] Although cognitive
scores and biomarker outcomes provide evidence of eﬃcacy
in phase II trials or in adaptive designs, large-scale trials with
functional outcomes due to cognitive or behavioural impair-
ment are needed to convince patients, doctors, regulators and
payers that treatments are worthwhile.
Relative to other outcomes, longer duration of
follow-up may be needed between intervention and
outcome measurement
Current science suggests a long latency between the opti-
mum period for intervention and the occurrence of demen-
tia. The problems of trials with a very long interval between
intervention and follow-up have not been resolved. A very
long period of intervention or the long-term follow-up of
patients in a trial with conventional methods probably would
be associated with substantial loss to follow-up (as seen
in long-duration cohort studies) unless linkage could be
performed to reliable electronic health records, or a par-
ticular group could be targeted who agree to take part in
low-intensity follow-up (e.g. web-form for cognitive tests,
implemented in UK Biobank) and dilution of treatment
eﬀects, unless multiple methods to encourage long-term
intervention adherence could be developed. However, long
trial interventions are possible; the Heart Outcomes Preven-
tion Evaluation-3 trial [43] trial of LDL and blood pressure
lowering had 6 years of intervention followed by 3 years of
follow-up, the UK Prospective Diabetes Study [44] of inten-
sive glucose lowering lasted 10 years, and trials of tamoxifen
in oestrogen receptor positive breast cancer compared treat-
ment durations of 10 with 5 years. [45] “One-oﬀ” therapies
with lasting eﬀects (e.g. gastric banding) might lead to diﬀer-
ences between randomised groups that last for many years.
If it is not the case that prevention requires a very long
period between intervention and symptoms, diﬀerences in
dementia incidence may be seen over a modest period (4–
5 years) if higher risk populations are recruited. For example,
SPRINT-MIND suggested a diﬀerence in dementia inci-
dence over 5 years with an annual dementia or MCI rate
of about 2 per 100 participant years.
For a preventative strategy to be adopted widely
for a common disease, it must be simple to deliver
If, for example, PET targeted intravenous amyloid reduc-
tion strategies prove to be eﬀective to reduce the rate of
4
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Table 2. Sample sizes for diﬀerent treatment eﬀects in a
two-arm trial, assuming a 5% drop-out rate over the course
of a 10-year trial with α = 0.05 and β = 0.8
% with outcome Hazard ratio between groups
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.80 0.85 0.90
5 13,275 25,025 59,542
10 6,638 12,513 29,771
15 4,425 8,342 19,848
Number of
outcomes needed
631 1,189 2,829
Alzheimer’s disease, this strategy could not be adopted widely
unless costs for both PET scanning and costs and burdens of
treatment fall substantially. Therefore, those treatments that
are feasible for testing in large simple trials are also those that
are most likely to be adopted widely.
Alternatives to large simple trial designs
The ﬁrst is to perform trials in smaller populations at
particularly high risk of inherited dementia, e.g. those with
a strong family history of dementia, those with extremes of
polygenic risk scores for all cause dementia or Alzheimer’s
disease or those with one or more high risk genetic variants
(e.g. APOE ε4 polymorphisms). The challenges faced by
such trials are the ethical and practical identiﬁcation of
potential participants and the possibility that trial results do
not generalise to the prevention of sporadic dementia in old
age (although there is a suggestion that similar pathways are
important in both young-onset familial disease and late onset
Alzheimer’s dementia) [16]. The beneﬁt is a tractable design
in a modest number of participants and short-duration
length of follow-up that identiﬁes a pathway that may be
exploited in larger studies.
The second is to power trials based on changes in
biomarkers that are known to be causally related to cognitive
and functional impairment. However, the most widely
used biomarkers of pathologies of cognitive impairment
are diﬃcult to deliver at large scale as their assessment is
expensive (e.g. markers of cerebral small vessel disease with
MRI, measurement of amyloid or tau by PET or in CSF)
and their association with clinical outcomes, particularly
at older ages, is not clearly causal. New, causally related
blood biomarkers might be discovered with Mendelian
randomisation designs that could be used as endpoints
in small trials. [46] Simpler biomarkers in blood (e.g.
neuroﬁlament light chain [47]) or computed tomography
measurement of aspects of cerebral small vessel disease may
make studies possible at lower cost. However, smaller and
shorter trials with biomarker endpoints may miss oﬀ target
adverse or beneﬁcial eﬀects.
The third is to acknowledge that there may be important
eﬀects to be found testing cognitive or functional measures
(or their combination in a validated algorithm) in large
studies of other agents. Many agents tested in cardiovascular
or other ﬁelds have potential eﬀects dementia pathological
pathways and beginning and end of study cognitive test
allows one to test these hypotheses at modest cost.
In comparison to these designs, large simple trials with
clinically important outcomes oﬀer the advantage of gen-
eralisability and validity of observed treatment eﬀects. If
such trials are to be delivered in dementia prevention, then
it is important to identify easily recruitable populations at
higher risk, important deliverable interventions and clini-
cally meaningful outcomes which can be measured easily.
Conclusion
If a large, simple dementia prevention trial with a clini-
cally relevant outcome were possible, it would be a major
challenge. Populations at high risk could be identiﬁed with
clinical variables, although only the oldest patients with
comorbidity (stroke or frailty) would have an estimated 10-
year risk of dementia of over 10% (Table 1). Participants
with these comorbidities would have similar risks to those
carrying APOE ε4. A long duration trial of a treatment
with a moderate but worthwhile eﬀect (e.g. a reduction
in relative hazards of 15%) in one of these populations
would need to recruit at least 8342 participants (Table 2),
and possibly more depending on the risk of competing
events. The most suitable targets are those targeting vascular
risk factors. Although trials examining complex vascular
risk interventions are underway, whether any one of the
components of these complex interventions has an eﬀect
on dementia is uncertain and would need to be clariﬁed to
ensure the optimum dementia prevention package.
A trial involving such a large number of participants
would need international co-operation, multiple academic
funders and strong engagement with communities of
patients and clinicians. Some consortiums have begun, but
to ensure healthy ageing for all across the world, we will
need to form new collaborations between many regions,
collaborators and patient organisations.
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